MovDisordV3, PascalFrancis, Corpus, bibRecord, 000F47

Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease

Identifieur interne : 000F47 ( PascalFrancis/Corpus ); précédent : 000F46; suivant : 000F48

Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease

Auteurs : Robert A. Hauser ; Mark F. Lew ; Howard I. Hurtig ; William G. Ondo ; Joanne Wojcieszek ; Cheryl J. Fitzer-Attas

Source :

Movement disorders [ 0885-3185 ] ; 2009.

RBID : Pascal:09-0171575

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Long terme, Pronostic, Etude comparative, Rasagiline, Traitement, Modification, Inhibiteur de la monoamine oxidase B.

English descriptors

KwdEn :
- Comparative study, Long term, Modification, Monoamine oxidase B inhibitor, Nervous system diseases, Parkinson disease, Prognosis, Rasagiline, Treatment.

Abstract

The purpose of this study was to compare the long-term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early-start group) or placebo for 6 months followed by rasagiline (delayed-start group) in the TEMPO study. Subjects who chose to participate in an open-label extension (N = 306) continued to receive rasagiline as well as other PD medications as needed. Average (±SD) duration in the study was 3.6 ± 2.1 years; 177 subjects received rasagiline for ≥5.0 years. Over the entire 6.5-year follow-up period, the adjusted mean difference in change from baseline in total UPDRS scores was 2.5 units (SE 1.1; P = 0.021) or 16% (SE 5.7; P = 0.006) in favor of the early-start versus delayed-start rasagiline group. Although the interaction between treatment and time was significant, values for the early-start group were better than the delayed-start group across all time points. Significantly less worsening (percent change) in total UPDRS scores was observed in the early-start group at the time points 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years (P < 0.05). Compared to delayed start, early initiation of rasagiline provided long-term clinical benefit, even in the face of treatment with other dopaminergic agents. This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 24`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease`
A11	`01`	`1`		`@1 HAUSER (Robert A.)`
A11	`02`	`1`		`@1 LEW (Mark F.)`
A11	`03`	`1`		`@1 HURTIG (Howard I.)`
A11	`04`	`1`		`@1 ONDO (William G.)`
A11	`05`	`1`		`@1 WOJCIESZEK (Joanne)`
A11	`06`	`1`		`@1 FITZER-ATTAS (Cheryl J.)`
A14	`01`			`@1 Parkinsons's Disease and Movement Disorders Center, University of South Florida @2 Tampa, Florida @3 USA @Z 1 aut.`
A14	`02`			`@1 Department of Neurology, Keck/University of Southern California School of Medicine @2 Los Angeles, California @3 USA @Z 2 aut.`
A14	`03`			`@1 Department of Neurology, Pennsylvania Hospital, University of Pennsylvania Health System @2 Philadelphia, Pennsylvania @3 USA @Z 3 aut.`
A14	`04`			`@1 Department of Neurology, Baylor College of Medicine @2 Houston, Texas @3 USA @Z 4 aut.`
A14	`05`			`@1 Department of Neurology, Indiana University School of Medicine @2 Indianapolis, Indiana @3 USA @Z 5 aut.`
A14	`06`			`@1 Teva Pharmaceutical Industries Ltd @2 Petach Tikva @3 ISR @Z 6 aut.`
A17	`01`	`1`		`@1 TEMPO Open-label Study Group @3 INC`
A20				`@1 564-573`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000187465460110`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 23 ref.`
A47	`01`	`1`		`@0 09-0171575`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The purpose of this study was to compare the long-term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early-start group) or placebo for 6 months followed by rasagiline (delayed-start group) in the TEMPO study. Subjects who chose to participate in an open-label extension (N = 306) continued to receive rasagiline as well as other PD medications as needed. Average (±SD) duration in the study was 3.6 ± 2.1 years; 177 subjects received rasagiline for ≥5.0 years. Over the entire 6.5-year follow-up period, the adjusted mean difference in change from baseline in total UPDRS scores was 2.5 units (SE 1.1; P = 0.021) or 16% (SE 5.7; P = 0.006) in favor of the early-start versus delayed-start rasagiline group. Although the interaction between treatment and time was significant, values for the early-start group were better than the delayed-start group across all time points. Significantly less worsening (percent change) in total UPDRS scores was observed in the early-start group at the time points 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years (P < 0.05). Compared to delayed start, early initiation of rasagiline provided long-term clinical benefit, even in the face of treatment with other dopaminergic agents. This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Long terme @5 09`
C03	`03`	`X`	`ENG`	`@0 Long term @5 09`
C03	`03`	`X`	`SPA`	`@0 Largo plazo @5 09`
C03	`04`	`X`	`FRE`	`@0 Pronostic @5 10`
C03	`04`	`X`	`ENG`	`@0 Prognosis @5 10`
C03	`04`	`X`	`SPA`	`@0 Pronóstico @5 10`
C03	`05`	`X`	`FRE`	`@0 Etude comparative @5 11`
C03	`05`	`X`	`ENG`	`@0 Comparative study @5 11`
C03	`05`	`X`	`SPA`	`@0 Estudio comparativo @5 11`
C03	`06`	`X`	`FRE`	`@0 Rasagiline @2 NK @2 FR @5 12`
C03	`06`	`X`	`ENG`	`@0 Rasagiline @2 NK @2 FR @5 12`
C03	`06`	`X`	`SPA`	`@0 Rasagilina @2 NK @2 FR @5 12`
C03	`07`	`X`	`FRE`	`@0 Traitement @5 13`
C03	`07`	`X`	`ENG`	`@0 Treatment @5 13`
C03	`07`	`X`	`SPA`	`@0 Tratamiento @5 13`
C03	`08`	`X`	`FRE`	`@0 Modification @5 14`
C03	`08`	`X`	`ENG`	`@0 Modification @5 14`
C03	`08`	`X`	`SPA`	`@0 Modificación @5 14`
C03	`09`	`X`	`FRE`	`@0 Inhibiteur de la monoamine oxidase B @5 15`
C03	`09`	`X`	`ENG`	`@0 Monoamine oxidase B inhibitor @5 15`
C03	`09`	`X`	`SPA`	`@0 Inhibidor monoamine oxidase B @5 15`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 124`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 09-0171575 INIST
ET :	Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease
AU :	HAUSER (Robert A.); LEW (Mark F.); HURTIG (Howard I.); ONDO (William G.); WOJCIESZEK (Joanne); FITZER-ATTAS (Cheryl J.)
AF :	Parkinsons's Disease and Movement Disorders Center, University of South Florida/Tampa, Florida/Etats-Unis (1 aut.); Department of Neurology, Keck/University of Southern California School of Medicine/Los Angeles, California/Etats-Unis (2 aut.); Department of Neurology, Pennsylvania Hospital, University of Pennsylvania Health System/Philadelphia, Pennsylvania/Etats-Unis (3 aut.); Department of Neurology, Baylor College of Medicine/Houston, Texas/Etats-Unis (4 aut.); Department of Neurology, Indiana University School of Medicine/Indianapolis, Indiana/Etats-Unis (5 aut.); Teva Pharmaceutical Industries Ltd/Petach Tikva/Israël (6 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 4; Pp. 564-573; Bibl. 23 ref.
LA :	Anglais
EA :	The purpose of this study was to compare the long-term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early-start group) or placebo for 6 months followed by rasagiline (delayed-start group) in the TEMPO study. Subjects who chose to participate in an open-label extension (N = 306) continued to receive rasagiline as well as other PD medications as needed. Average (±SD) duration in the study was 3.6 ± 2.1 years; 177 subjects received rasagiline for ≥5.0 years. Over the entire 6.5-year follow-up period, the adjusted mean difference in change from baseline in total UPDRS scores was 2.5 units (SE 1.1; P = 0.021) or 16% (SE 5.7; P = 0.006) in favor of the early-start versus delayed-start rasagiline group. Although the interaction between treatment and time was significant, values for the early-start group were better than the delayed-start group across all time points. Significantly less worsening (percent change) in total UPDRS scores was observed in the early-start group at the time points 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years (P < 0.05). Compared to delayed start, early initiation of rasagiline provided long-term clinical benefit, even in the face of treatment with other dopaminergic agents. This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Pathologie du système nerveux; Long terme; Pronostic; Etude comparative; Rasagiline; Traitement; Modification; Inhibiteur de la monoamine oxidase B
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Nervous system diseases; Long term; Prognosis; Comparative study; Rasagiline; Treatment; Modification; Monoamine oxidase B inhibitor
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Sistema nervioso patología; Largo plazo; Pronóstico; Estudio comparativo; Rasagilina; Tratamiento; Modificación; Inhibidor monoamine oxidase B
LO :	INIST-20953.354000187465460110
ID :	09-0171575

Links to Exploration step

Pascal:09-0171575

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinsons's Disease and Movement Disorders Center, University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lew, Mark F" sort="Lew, Mark F" uniqKey="Lew M" first="Mark F." last="Lew">Mark F. Lew</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Keck/University of Southern California School of Medicine</s1>
<s2>Los Angeles, California</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I." last="Hurtig">Howard I. Hurtig</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Pennsylvania Hospital, University of Pennsylvania Health System</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, Indiana University School of Medicine</s1>
<s2>Indianapolis, Indiana</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fitzer Attas, Cheryl J" sort="Fitzer Attas, Cheryl J" uniqKey="Fitzer Attas C" first="Cheryl J." last="Fitzer-Attas">Cheryl J. Fitzer-Attas</name>
<affiliation><inist:fA14 i1="06"><s1>Teva Pharmaceutical Industries Ltd</s1>
<s2>Petach Tikva</s2>
<s3>ISR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0171575</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0171575 INIST</idno>
<idno type="RBID">Pascal:09-0171575</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F47</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinsons's Disease and Movement Disorders Center, University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lew, Mark F" sort="Lew, Mark F" uniqKey="Lew M" first="Mark F." last="Lew">Mark F. Lew</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Keck/University of Southern California School of Medicine</s1>
<s2>Los Angeles, California</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I." last="Hurtig">Howard I. Hurtig</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Pennsylvania Hospital, University of Pennsylvania Health System</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, Indiana University School of Medicine</s1>
<s2>Indianapolis, Indiana</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fitzer Attas, Cheryl J" sort="Fitzer Attas, Cheryl J" uniqKey="Fitzer Attas C" first="Cheryl J." last="Fitzer-Attas">Cheryl J. Fitzer-Attas</name>
<affiliation><inist:fA14 i1="06"><s1>Teva Pharmaceutical Industries Ltd</s1>
<s2>Petach Tikva</s2>
<s3>ISR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Comparative study</term>
<term>Long term</term>
<term>Modification</term>
<term>Monoamine oxidase B inhibitor</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Prognosis</term>
<term>Rasagiline</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Long terme</term>
<term>Pronostic</term>
<term>Etude comparative</term>
<term>Rasagiline</term>
<term>Traitement</term>
<term>Modification</term>
<term>Inhibiteur de la monoamine oxidase B</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The purpose of this study was to compare the long-term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early-start group) or placebo for 6 months followed by rasagiline (delayed-start group) in the TEMPO study. Subjects who chose to participate in an open-label extension (N = 306) continued to receive rasagiline as well as other PD medications as needed. Average (±SD) duration in the study was 3.6 ± 2.1 years; 177 subjects received rasagiline for ≥5.0 years. Over the entire 6.5-year follow-up period, the adjusted mean difference in change from baseline in total UPDRS scores was 2.5 units (SE 1.1; P = 0.021) or 16% (SE 5.7; P = 0.006) in favor of the early-start versus delayed-start rasagiline group. Although the interaction between treatment and time was significant, values for the early-start group were better than the delayed-start group across all time points. Significantly less worsening (percent change) in total UPDRS scores was observed in the early-start group at the time points 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years (P < 0.05). Compared to delayed start, early initiation of rasagiline provided long-term clinical benefit, even in the face of treatment with other dopaminergic agents. This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>24</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HAUSER (Robert A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LEW (Mark F.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HURTIG (Howard I.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>ONDO (William G.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>WOJCIESZEK (Joanne)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>FITZER-ATTAS (Cheryl J.)</s1>
</fA11>
<fA14 i1="01"><s1>Parkinsons's Disease and Movement Disorders Center, University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, Keck/University of Southern California School of Medicine</s1>
<s2>Los Angeles, California</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, Pennsylvania Hospital, University of Pennsylvania Health System</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, Indiana University School of Medicine</s1>
<s2>Indianapolis, Indiana</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Teva Pharmaceutical Industries Ltd</s1>
<s2>Petach Tikva</s2>
<s3>ISR</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>TEMPO Open-label Study Group</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>564-573</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000187465460110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>23 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0171575</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The purpose of this study was to compare the long-term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early-start group) or placebo for 6 months followed by rasagiline (delayed-start group) in the TEMPO study. Subjects who chose to participate in an open-label extension (N = 306) continued to receive rasagiline as well as other PD medications as needed. Average (±SD) duration in the study was 3.6 ± 2.1 years; 177 subjects received rasagiline for ≥5.0 years. Over the entire 6.5-year follow-up period, the adjusted mean difference in change from baseline in total UPDRS scores was 2.5 units (SE 1.1; P = 0.021) or 16% (SE 5.7; P = 0.006) in favor of the early-start versus delayed-start rasagiline group. Although the interaction between treatment and time was significant, values for the early-start group were better than the delayed-start group across all time points. Significantly less worsening (percent change) in total UPDRS scores was observed in the early-start group at the time points 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years (P < 0.05). Compared to delayed start, early initiation of rasagiline provided long-term clinical benefit, even in the face of treatment with other dopaminergic agents. This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Long terme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Long term</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Rasagiline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Rasagiline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Rasagilina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Traitement</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Treatment</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Modification</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Modification</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Modificación</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Inhibiteur de la monoamine oxidase B</s0>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Monoamine oxidase B inhibitor</s0>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Inhibidor monoamine oxidase B</s0>
<s5>15</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>124</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0171575 INIST</NO>
<ET>Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease</ET>
<AU>HAUSER (Robert A.); LEW (Mark F.); HURTIG (Howard I.); ONDO (William G.); WOJCIESZEK (Joanne); FITZER-ATTAS (Cheryl J.)</AU>
<AF>Parkinsons's Disease and Movement Disorders Center, University of South Florida/Tampa, Florida/Etats-Unis (1 aut.); Department of Neurology, Keck/University of Southern California School of Medicine/Los Angeles, California/Etats-Unis (2 aut.); Department of Neurology, Pennsylvania Hospital, University of Pennsylvania Health System/Philadelphia, Pennsylvania/Etats-Unis (3 aut.); Department of Neurology, Baylor College of Medicine/Houston, Texas/Etats-Unis (4 aut.); Department of Neurology, Indiana University School of Medicine/Indianapolis, Indiana/Etats-Unis (5 aut.); Teva Pharmaceutical Industries Ltd/Petach Tikva/Israël (6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 4; Pp. 564-573; Bibl. 23 ref.</SO>
<LA>Anglais</LA>
<EA>The purpose of this study was to compare the long-term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early-start group) or placebo for 6 months followed by rasagiline (delayed-start group) in the TEMPO study. Subjects who chose to participate in an open-label extension (N = 306) continued to receive rasagiline as well as other PD medications as needed. Average (±SD) duration in the study was 3.6 ± 2.1 years; 177 subjects received rasagiline for ≥5.0 years. Over the entire 6.5-year follow-up period, the adjusted mean difference in change from baseline in total UPDRS scores was 2.5 units (SE 1.1; P = 0.021) or 16% (SE 5.7; P = 0.006) in favor of the early-start versus delayed-start rasagiline group. Although the interaction between treatment and time was significant, values for the early-start group were better than the delayed-start group across all time points. Significantly less worsening (percent change) in total UPDRS scores was observed in the early-start group at the time points 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years (P < 0.05). Compared to delayed start, early initiation of rasagiline provided long-term clinical benefit, even in the face of treatment with other dopaminergic agents. This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Pathologie du   système nerveux; Long terme; Pronostic; Etude comparative; Rasagiline; Traitement; Modification; Inhibiteur de la monoamine oxidase B</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Long term; Prognosis; Comparative study; Rasagiline; Treatment; Modification; Monoamine oxidase B inhibitor</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; Largo plazo; Pronóstico; Estudio comparativo; Rasagilina; Tratamiento; Modificación; Inhibidor monoamine oxidase B</SD>
<LO>INIST-20953.354000187465460110</LO>
<ID>09-0171575</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F47 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000F47 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0171575
   |texte=   Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease

Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri